Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$118.49

0.93 (0.79%)

, PFE

Pfizer

$32.50

-0.16 (-0.49%)

17:49
10/17/16
10/17
17:49
10/17/16
17:49

J&J trades lower after Pfizer announces availability of Remicade biosimilar

Shares of Johnson & Johnson (JNJ) are fractionally lower, down 0.41%, or 49c to $118 per share in after-hours trading after Pfizer (PFE) announced that the company will begin shipment of INFLECTRA for injection, a biosimilar of REMICADE to wholesalers in the United States in late November 2016.

JNJ

Johnson & Johnson

$118.49

0.93 (0.79%)

PFE

Pfizer

$32.50

-0.16 (-0.49%)

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

  • 06

    Nov

JNJ Johnson & Johnson
$118.49

0.93 (0.79%)

10/07/16
RBCM
10/07/16
NO CHANGE
RBCM
Johnson & Johnson weakness creates buying opportunity, says RBC Capital
RBC Capital analyst Glenn Novarro says that Johnson & Johnson underperformed the market in Q3 due to a number of factors including Remicade biosimilar risk and the pharma pricing debate. The analyst says that "these concerns are manageable/overblown," and he expects the company to report strong Q3 results, driven by a strong pharma performance. Novoroo expects the company's Q3 revenue to come in slightly above expectations, and he predicts that the company will narrow its 2016 EPS guidance to the high end of the previous range. The analyst recommends buying the stock. He keeps a $133 price target and Outperform rating on the shares.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
08/24/16
JEFF
08/24/16
NO CHANGE
Target $210
JEFF
Buy
Cooper Companies estimates raised at Jefferies after doctor survey
Jefferies analyst Anthony Petrone reports that the firm's survey of 52 new optometry practices suggest continued gains in dailies and stable share in monthlies for Cooper Companies (COO) and that Johnson & Johnson's (JNJ) Acuvue Vita is off to slow start. Based on the survey results, and a "significant" foreign exchange tailwind, Petrone raised his estimates for Cooper and increased his price target on the shares to $210 from $190. The firm has a Buy rating on Cooper shares.
PFE Pfizer
$32.50

-0.16 (-0.49%)

10/13/16
10/13/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Buy from Conviction Buy at Goldman with analyst Jami Rubin saying disappointing CM-26 data adds a greater level of uncertainty to future trials. 2. Pfizer (PFE) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing a lack of positive catalysts. 3. Coach (COH) downgraded to Mixed from Positive at OTR Global citing checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers. 4. E-Trade (ETFC) downgraded to Neutral from Buy at BofA/Merrill. 5. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
10/07/16
ROTH
10/07/16
NO CHANGE
Target $160
ROTH
Buy
ICU Medical price target raised to $160 from $132 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for ICU Medical (ICUI) to $160 from $132 after the company announced an agreement to acquire Hospira Infusion Systems from Pfizer (PFE) for $1B. The analyst is overall positive on the deal as it removes the long-standing customer concentration overhang and grows ICU Medical into a legitimate pure-play infusion therapy company with a complete product portfolio. The company also preannounced Q3 preliminary results above expectations, he notes. Lewis reiterates a Buy rating on ICU Medical's shares.
09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.

TODAY'S FREE FLY STORIES

PSTG

Pure Storage

$12.16

-0.17 (-1.38%)

14:12
12/09/16
12/09
14:12
12/09/16
14:12
Conference/Events
Pure Storage participates in a conference call with Stifel »

Stifel's Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 12

    Jan

  • 13

    Jan

  • 09

    Dec

IX

ORIX Corp

$82.04

0.99 (1.22%)

14:10
12/09/16
12/09
14:10
12/09/16
14:10
Upgrade
ORIX Corp rating change  »

ORIX Corp upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$15.43

0.585 (3.94%)

14:10
12/09/16
12/09
14:10
12/09/16
14:10
Options
Transocean short-term puts active as shares see strength »

Transocean short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NMR

Nomura

$6.70

0.22 (3.40%)

14:08
12/09/16
12/09
14:08
12/09/16
14:08
Upgrade
Nomura rating change  »

Nomura upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$57.13

-0.06 (-0.10%)

14:06
12/09/16
12/09
14:06
12/09/16
14:06
Downgrade
MetLife rating change  »

MetLife downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

14:05
12/09/16
12/09
14:05
12/09/16
14:05
General news
Treasury Action: next week's auctions could be difficult »

Treasury Action: next…

QQQ

NASDAQ 100 Index Tracking Stock

$118.57

0.21 (0.18%)

14:00
12/09/16
12/09
14:00
12/09/16
14:00
Options
Bullish yearend play in the PowerShares QQQ ETF »

Bullish yearend play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
12/09/16
12/09
13:50
12/09/16
13:50
General news
Action Economics Survey results: equities continue to charge ahead »

Action Economics Survey…

CFX

Colfax

$39.04

-0.245 (-0.62%)

13:49
12/09/16
12/09
13:49
12/09/16
13:49
Conference/Events
Colfax to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

13:45
12/09/16
12/09
13:45
12/09/16
13:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY moved…

NRE

Northstar Realty Europe Corp.

$12.13

0.36 (3.06%)

, NSAM

NorthStar Asset Management

$15.09

0.09 (0.60%)

13:44
12/09/16
12/09
13:44
12/09/16
13:44
Hot Stocks
Bow Street confirms $13 per share offer for Northstar Realty Europe Corp. »

Bow Street, which holds a…

NRE

Northstar Realty Europe Corp.

$12.13

0.36 (3.06%)

NSAM

NorthStar Asset Management

$15.09

0.09 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

CALA

Calithera Biosciences

$3.20

-0.05 (-1.54%)

13:44
12/09/16
12/09
13:44
12/09/16
13:44
Conference/Events
Calithera Biosciences to hold a conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BAC

Bank of America

$23.03

0.075 (0.33%)

13:40
12/09/16
12/09
13:40
12/09/16
13:40
Options
Eight year highs and flat skew draw ratio call spreader in Bank of America »

Eight year highs and flat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jan

VIA

Viacom

$42.60

0.45 (1.07%)

, VIAB

Viacom

$38.80

0.79 (2.08%)

13:37
12/09/16
12/09
13:37
12/09/16
13:37
Hot Stocks
Box Office Battle: 'Office Christmas Party' looks to topple 'Moana' »

Opening this weekend, and…

VIA

Viacom

$42.60

0.45 (1.07%)

VIAB

Viacom

$38.80

0.79 (2.08%)

CMCSK

Comcast

CMCSA

Comcast

$69.23

-0.1 (-0.14%)

SNE

Sony

$29.40

0.24 (0.82%)

FOXA

21st Century Fox

$28.64

0.53 (1.89%)

FOX

21st Century Fox

$28.48

0.53 (1.90%)

DIS

Disney

$103.84

0.46 (0.44%)

TWX

Time Warner

$94.89

0.34 (0.36%)

LGF

Lionsgate

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VHC

VirnetX

$2.95

-0.35 (-10.61%)

, AAPL

Apple

$112.12

1.09 (0.98%)

13:32
12/09/16
12/09
13:32
12/09/16
13:32
Hot Stocks
VirnetX says U.S. Federal Circuit Appeals Court issued three appeal decisions »

VirnetX announced that on…

VHC

VirnetX

$2.95

-0.35 (-10.61%)

AAPL

Apple

$112.12

1.09 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

AFL

Aflac

$68.79

-0.83 (-1.19%)

13:25
12/09/16
12/09
13:25
12/09/16
13:25
Options
AFLAC call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
12/09/16
12/09
13:25
12/09/16
13:25
General news
Energy Action: Weekly Baker-Hughes rig count »

Energy Action: Weekly…

TTI

TETRA

$4.61

-0.4 (-7.98%)

13:20
12/09/16
12/09
13:20
12/09/16
13:20
Downgrade
TETRA rating change  »

TETRA downgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

$NYE

NYSE Market Internals

13:16
12/09/16
12/09
13:16
12/09/16
13:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:16
12/09/16
12/09
13:16
12/09/16
13:16
Technical Analysis
NASDAQ market internals summary »

Volume is extremely heavy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$225.83

0.68 (0.30%)

, XLF

Financial Select Sector

$23.64

-0.06 (-0.25%)

13:13
12/09/16
12/09
13:13
12/09/16
13:13
Technical Analysis
On The Fly: ETF fund flow highlights »

The week saw very large…

SPY

SPDR S&P 500 ETF Trust

$225.83

0.68 (0.30%)

XLF

Financial Select Sector

$23.64

-0.06 (-0.25%)

XLP

Consumer Staples Sector SPDR

$51.86

0.56 (1.09%)

XLI

Industrial Select Sector SPDR

$63.87

0.18 (0.28%)

VOO

Vanguard S&P 500 ETF

$207.39

0.65 (0.31%)

JNK

SPDR Barclays High Yield Bond

$36.47

0.0085 (0.02%)

IEMG

iShares Core MSCI Emerging Markets

$43.94

-0.165 (-0.37%)

QQQ

NASDAQ 100 Index Tracking Stock

$118.57

0.21 (0.18%)

USO

United States Oil Fund

$11.42

0.11 (0.97%)

XOP

SPDR Oil Exploration and Production Fund

$43.19

-0.16 (-0.37%)

UWTI

VelocityShares 3x Long Crude Oil ETN

IBB

iShares Nasdaq Biotechnology Index

$268.52

2.24 (0.84%)

GLD

SPDR Gold Trust

$110.63

-0.94 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTI

TETRA

$4.61

-0.4 (-7.98%)

13:12
12/09/16
12/09
13:12
12/09/16
13:12
Downgrade
TETRA rating change  »

TETRA downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

IRM

Iron Mountain

$34.71

-0.28 (-0.80%)

13:11
12/09/16
12/09
13:11
12/09/16
13:11
Hot Stocks
Iron Mountain receives approval to sell C21 to Oasis Group »

Iron Mountain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$289.54

4.24 (1.49%)

13:10
12/09/16
12/09
13:10
12/09/16
13:10
Hot Stocks
Biogen off highs after disclosing serious adverse event in Alzheimer's trial »

Shares of Biogen are well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$29.28

0.63 (2.20%)

13:10
12/09/16
12/09
13:10
12/09/16
13:10
Options
MGM calls active as shares move off session highs »

MGM calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.